Malignant Neoplasms of Lip Oral Cavity and Pharynx Recruiting Phase 1 / 2 Trials for Avelumab (DB11945)

IndicationStatusPhase
DBCOND0081505 (Malignant Neoplasms of Lip Oral Cavity and Pharynx)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03217747Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesTreatment